It wasn’t all that long ago that anti-VEGF therapy and surgeries like DSEK and DSAEK were novel, promising but still unproven approaches to ocular diseases and conditions. It’s a reflection of their success that many of this year’s ARVO abstracts are reporting long-term studies of these therapies and a broadening range of diseases that are potential targets for further study.
So it is with the annual meeting of the Association for Research in Vision and Ophthalmology. Which of this year’s novel surgical techniques, technological advances and innovative drug therapies will rise to the top, only time will tell. We hope that in these few pages, we can give an early look at the most promising candidates.
The abstracts shown here were culled by the staff at the Review from thousands of online ARVO abstracts in six subspecialty areas. Then, with assistance of our various Section Editors and contributing physicians, we further focused on those that may have the most clinical applicability, noteworthiness or potential for significant impact on your patients. Though the final result highlights hundreds of worthy research reports, they are just a snapshot of the full range of work on display at the ARVO meeting.
We hope these brief reports encourage you to review the abstracts more fully online at arvo.org, and if you’re in Florida for the meeting, to visit the posters for updated, first-hand information from the authors. At the end of each abstract’s description in our reports, you’ll see a reference number, which indicates its ARVO program number.
Click on the following links to jump to a new section: